CIK 0001326190
- Non-accelerated filer
- Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 202726770
- Phone
- +1 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $82,244
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$82,244. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-10-13 | SAYARE MITCHEL Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2017-10-13 | SCHAFFER DERACE L Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2017-10-13 | Schafer Klaus Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2017-10-13 | GILL JOHN Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2017-10-13 | Drutz David Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2017-10-13 | Hodges Philip Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2017-09-22 | Tasker Sybil Chief Medical Officer | Grant or award · Stock Options (option to buy) | +50,000 | 50,000 | ||
| 2017-09-22 | Roberts M Scot Chief Scientific Officer | Grant or award · Stock Options (option to buy) | +50,000 | 50,000 | ||
| 2017-09-22 | Enright William President and CEO | Grant or award · Stock Options (option to buy) | +125,000 | 125,000 | ||
| 2017-09-22 | CZEREPAK ELIZABETH CFO and EVP Corp. Development | Grant or award · Stock Options (option to buy) | +62,500 | 62,500 | ||
| 2017-09-22 | CZEREPAK ELIZABETH CFO and EVP Corp. Development | Grant or award · Stock Options (option to buy) | +62,500 | 62,500 | ||
| 2017-08-25 | SCHAFFER DERACE L Director | Purchase | +50,000 | $2.25 | $112K | 221,704 |
| 2017-08-24 | SCHAFFER DERACE L Director | Purchase | +17,326 | $2.24 | $39K | 171,704 |
| 2017-08-23 | Drutz David Director | Purchase | +5,000 | $2.27 | $11K | 30,777 |
| 2017-08-23 | SCHAFFER DERACE L Director | Purchase | +43,352 | $2.22 | $96K | 154,378 |
| 2017-08-22 | Drutz David Director | Purchase | +5,000 | $2.15 | $11K | 25,777 |
| 2017-08-22 | SCHAFFER DERACE L Director | Purchase | +5,958 | $2.10 | $13K | 111,026 |
| 2017-08-21 | SCHAFFER DERACE L Director | Purchase | +690 | $2.02 | $1K | 105,068 |
| 2017-08-21 | Truffle Capital S.A.S. 10% owner | Purchase · Series B Convertible Preferred Stock | +204.89 | $940.00 | $193K | 204.89 |
| 2017-08-21 | Truffle Capital S.A.S. 10% owner | Purchase · Series B Convertible Preferred Stock | +273.19 | $940.00 | $257K | 273.19 |
Page 30 of 43 · 845 trades